Evotec rebounded in Q4
Evotec SE rebounded in the fourth quarter of 2022 producing a 29% gain in revenue for the strongest quarter in the company’s history. Revenue for the quarter was €240.7 million, making the total for the year €751.4 million, up by 22% compared with 2021. The company’s service business, which ranges from drug discovery to manufacturing and clinical development, remained strong. In 2022, the company was involved in more than 800 alliances and recorded a repeat business of 92%.
